Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.
1 report, 0 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Deutsche Bank
German global banking and financial services company
-
Repligen
bioTech Company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet